T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
CMS Energy
CMS
$22.1B
| $24.5M | 0.01% |
533,171
-100
| -0% | -$4.2K |
|
1027
Labcorp
LH
$26.1B
| $24.4M | 0.01% |
217,762
-501
| -0.2% | -$53.9K |
|
1028
Euronet Worldwide
EEFT
$2.68B
| $24.4M | 0.01% |
352,053
+7,363
| +2% | +$560K |
|
1029
Simmons First National
SFNC
$3.47B
| $24.3M | 0.01% |
1,051,780
-37,580
| -3% | -$863K |
|
1030
Perrigo
PRGO
$1.75B
| $24.1M | 0.01% |
265,700
-179,578
| -40% | -$18.6M |
|
1031
Jack Henry & Associates
JKHY
$10.8B
| $24.1M | 0.01% |
275,889
+5,419
| +2% | +$453K |
|
1032
Live Nation Entertainment
LYV
$43.3B
| $23.9M | 0.01% |
1,019,101
-23,602
| -2% | -$539K |
|
1033
Winmark
WINA
$1.27B
| $23.8M | 0.01% |
238,913
+4,623
| +2% | +$450K |
|
1034
Graham Holdings Company
GHC
$5B
| $23.8M | 0.01% |
48,622
+46,505
| +2,197% | +$22.7M |
|
1035
Duluth Holdings
DLTH
$153M
| $23.8M | 0.01% |
971,820
| – | – |
|
|
TVPT
1036
DELISTED
Travelport Worldwide Limited
TVPT
| $23.7M | 0.01% |
1,839,400
+1,290,000
| +235% | +$17.3M |
|
1037
Teck Resources
TECK
$31.6B
| $23.7M | 0.01% |
1,797,189
-109,080
| -6% | -$1.13M |
|
1038
Atlantic Union Bankshares
AUB
$6.1B
| $23.7M | 0.01% |
957,730
+4,100
| +0.4% | +$106K |
|
1039
PTC
PTC
$15.9B
| $23.6M | 0.01% |
628,753
+13,051
| +2% | +$468K |
|
1040
Luxfer Holdings
LXFR
$457M
| $23.6M | 0.01% |
1,960,930
| – | – |
|
|
IBTX
1041
DELISTED
Independent Bank Group, Inc.
IBTX
| $23.6M | 0.01% |
549,250
+93,220
| +20% | +$3.32M |
|
1042
Charles River Laboratories
CRL
$13.7B
| $23.5M | 0.01% |
285,314
+88,189
| +45% | +$7.26M |
|
|
TAHO
1043
DELISTED
Tahoe Resources Inc
TAHO
| $23.4M | 0.01% |
+1,573,678
| New | +$20.1M |
|
1044
Ameren
AEE
$30.2B
| $23.4M | ﹤0.01% |
435,914
-4,000
| -0.9% | -$197K |
|
1045
Marriott Vacations Worldwide
VAC
$4.14B
| $23.3M | ﹤0.01% |
340,338
-12,390
| -4% | -$776K |
|
|
GNMK
1046
DELISTED
GenMark Diagnostics, Inc
GNMK
| $23.2M | ﹤0.01% |
2,668,754
-1,400
| -0.1% | -$9.6K |
|
|
LDL
1047
DELISTED
Lydall, Inc.
LDL
| $23.2M | ﹤0.01% |
600,760
+1,400
| +0.2% | +$51.8K |
|
1048
MACOM Technology Solutions
MTSI
$24.2B
| $23.2M | ﹤0.01% |
701,960
+92,230
| +15% | +$3.5M |
|
1049
Extra Space Storage
EXR
$31.4B
| $22.8M | ﹤0.01% |
246,590
+15,900
| +7% | +$1.44M |
|
|
XTLY
1050
DELISTED
Xactly Corporation
XTLY
| $22.8M | ﹤0.01% |
1,779,200
-91,300
| -5% | -$849K |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.